These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34879208)

  • 1. Off-label direct oral anticoagulants dosing in atrial fibrillation and venous thromboembolism is associated with higher mortality.
    Aguilar F; Lo KB; Quintero EE; Torres RJ; Hung WA; Albano JC; Alviz I; Rodriguez C; Garcia MJ; Romero J; Slipczuk L
    Expert Rev Cardiovasc Ther; 2021 Dec; 19(12):1119-1126. PubMed ID: 34879208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis.
    Zhang XL; Zhang XW; Wang TY; Wang HW; Chen Z; Xu B; Xu W
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007971. PubMed ID: 34932377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States.
    Sandhu A; Kaltenbach LA; Chiswell K; Shimoga V; Ashur C; Pribish A; Fonarow GC; Piccini JP; Ho PM; Varosy PD; Hess PL
    Circ Cardiovasc Qual Outcomes; 2023 Dec; 16(12):e010062. PubMed ID: 37929603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.
    Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing.
    Cho MS; Yun JE; Park JJ; Kim YJ; Lee J; Kim H; Park DW; Nam GB
    Am J Cardiol; 2020 May; 125(9):1332-1338. PubMed ID: 32098658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Outcomes of Off-Label Underdosing of Direct Oral Anticoagulants After Ablation for Atrial Fibrillation.
    Wakamatsu Y; Nagashima K; Watanabe R; Arai M; Yokoyama K; Matsumoto N; Otsuka T; Suzuki S; Hirata A; Murakami M; Takami M; Kimura M; Fukaya H; Nakahara S; Kato T; Hayashi H; Iwasaki YK; Shimizu W; Nakajima I; Harada T; Koyama J; Okumura K; Tokuda M; Yamane T; Tanimoto K; Momiyama Y; Nonoguchi N; Soejima K; Ejima K; Hagiwara N; Harada M; Sonoda K; Inoue M; Kumagai K; Hayashi H; Yazaki Y; Satomi K; Watari Y; Okumura Y
    Int Heart J; 2020 Nov; 61(6):1165-1173. PubMed ID: 33191353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.
    Chan YH; Chao TF; Chen SW; Lee HF; Yeh YH; Huang YC; Chang SH; Kuo CT; Lip GYH; Chen SA
    Heart Rhythm; 2020 Dec; 17(12):2102-2110. PubMed ID: 32702416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
    J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment.
    Ting C; Rhoten M; Dempsey J; Nichols H; Fanikos J; Ruff CT
    Clin Appl Thromb Hemost; 2021; 27():1076029620987900. PubMed ID: 33517715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
    Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
    BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry.
    Murata N; Okumura Y; Yokoyama K; Matsumoto N; Tachibana E; Kuronuma K; Oiwa K; Matsumoto M; Kojima T; Hanada S; Nomoto K; Arima K; Takahashi F; Kotani T; Ikeya Y; Fukushima S; Itoh S; Kondo K; Chiku M; Ohno Y; Onikura M; Hirayama A;
    Circ J; 2019 Mar; 83(4):727-735. PubMed ID: 30726797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter.
    Ashraf H; Agasthi P; Shanbhag A; Mehta RA; Rattanawong P; Allam M; Pujari SH; Mookadam F; Freeman WK; Srivathsan K; Sorajja D; Shen WK; Noseworthy PA; Yang EH; Masry HZE; Yao X; Mulpuru SK; Beohar N; Holmes DR; Arsanjani R
    Am J Med; 2021 Jun; 134(6):788-796. PubMed ID: 33444586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism.
    Saunders JA; Gustafson WL; Vazquez SR; Jones AE; Witt DM
    J Thromb Thrombolysis; 2019 Oct; 48(3):506-510. PubMed ID: 31230262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardiopulmonary Disease.
    Hussein AA; Alvarez P; Reed G; Heresi GA
    Chest; 2022 May; 161(5):1360-1369. PubMed ID: 35101404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Updated Pooled Analysis of Off-Label Under and Over-Dosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation.
    Shen NN; Ferroni E; Amidei CB; Canova C; Peron V; Wang JL; Lin HW; Gu ZC
    Clin Appl Thromb Hemost; 2023; 29():10760296231179439. PubMed ID: 37264798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Oral Anticoagulant Dosing and Adherence to Therapy Among Patients With Nonvalvular Atrial Fibrillation.
    Rymer JA; Chiswell K; Young L; Chiu A; Liu L; Webb L; Carlisle M; Friedman D; Wang TY
    JAMA Netw Open; 2023 Jun; 6(6):e2317156. PubMed ID: 37285155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inappropriate prescriptions of direct oral anticoagulants (DOACs) in hospitalized patients: A narrative review.
    van der Horst SFB; van Rein N; van Mens TE; Huisman MV; Klok FA
    Thromb Res; 2023 Nov; 231():135-140. PubMed ID: 37005194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.